`21st-Century' Facility Is Bound For Seattle

In an era marked by the growing interdisciplinary nature of science, this new program will call on specialists from disparate fields such as physics, computer science, chemical engineering, and applied mathematics to tackle current problems in molecular biology. Their goal, in Hood's words, will be no less than to "develop the tools that are going to push us into the 21st century." Funded by a $12 million gift from William Gates III, founder and chairman of the Microsoft Corp. of nearby Redm

Written bySusan L-J Dickinson
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

In an era marked by the growing interdisciplinary nature of science, this new program will call on specialists from disparate fields such as physics, computer science, chemical engineering, and applied mathematics to tackle current problems in molecular biology. Their goal, in Hood's words, will be no less than to "develop the tools that are going to push us into the 21st century."

Funded by a $12 million gift from William Gates III, founder and chairman of the Microsoft Corp. of nearby Redmond, Wash., the charter of the new department will be to develop techniques and instruments that further the study of fundamental problems of modern biology, such as DNA sequencing, DNA diagnostics, and gene mapping.

1. New DNA Diagnostics and Genetic Mapping Instrumentation. The group hopes to expand and automate the process whereby genes are mapped and genetic diseases characterized. 2. Automated DNA Sequencer. In 1986, Hood's lab developed the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies